Injurytalk.com - Brought to you by Parker Waichman Alonso Mark, LLP

The following is just an excerpt of some of the facts I have found out about this drug. My 17 year old son was recently prescribed this "medication"...  :evil:

Pfizer Inc. (Pfizer) has promoted Geodon in a manner that is misleading and lacking fair balance because it minimizes the important risk information regarding the greater capacity of Geodon to cause QT prolongation, and the potential to cause torsade de pointes-type arrhythmia and sudden death.  For example, DDMAC objects to the following claims by Pfizer:
  No torsade de pointes
A rare incidence of a QTc interval >500 msec 
A well-characterized ECG profile 
Postmarketing experience ...
.......consistent with the Geodon clinical trial database

These statements, isolated out of context by bulleting, headlining, or other means, are misleading because they suggest that Geodon is safer than has been demonstrated by substantial evidence.  The Indications and Usage section of the approved product labeling (PI) for Geodon states that ziprasidone has a "greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs" and that this effect "is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death.  Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known." Furthermore, the bolded warning of the PI discusses the concern regarding QT prolongation, torsade de pointes, and the risk of sudden death, including the fact that although torsade de pointes has not been observed in pre-marketing studies, "experience is too limited to rule out an increased risk,"